FDA says mifepristone safety review will run into 2027 in court filing
Published · Updated
What happened
The FDA told a court in a filing on October 7, 2026 that its ongoing safety review of mifepristone will continue into 2027, with a study expected by mid-December 2026 and a report expected by March 2027.
Why it matters
The filing extends a live federal review of a widely used drug and sets new administrative milestones that can shape litigation timing, prescribing expectations, and political pressure on HHS and the FDA.
The Food and Drug Administration said in a court-ordered filing late on October 7 that its safety review of mifepristone will continue into next year. The filing said a study is expected by mid-December and a report by March 2027. The update keeps an active federal review of a nationally used abortion drug on the administrative and legal calendar, extending pressure on FDA and HHS as they balance drug-safety process, litigation exposure, and public trust.
Watch for
U.S. District Court docket entry setting the next briefing or compliance deadline for the FDA on or after 2026-10-08 HHS or FDA release specifying the scope and methods of the mifepristone safety study on or after 2026-10-08 Department of Justice filing on behalf of FDA addressing timetable, scope, or relief in the mifepristone case within 72 hours FDA acknowledgement of whether existing mifepristone labeling or REMS requirements remain unchanged during the review on or after 2026-10-08
Researched and written by AI from the sources listed, under published rules. How V³ Aware is made